A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Active:	No
Cancer Type:	Hodgkin Lymphoma Lymphoma Non-Hodgkin Lymphoma	NCT ID:	NCT05181540
Trial Phases:	Phase III	Protocol IDs:	AB-205-301 (primary) NCI-2022-00998
Eligibility:	40 Years and older, Male and Female	Study Type:	Supportive care
Study Sponsor:	Angiocrine Bioscience
NCI Full Details:	http://clinicaltrials.gov/show/NCT05181540

Summary

High-dose chemotherapy followed by blood stem cell transplantation is administered to
lymphoma patients with an intention to cure. However, high-dose chemotherapy
simultaneously causes damage to healthy tissues that frequently result in severe
complications that lead to hospitalization and can be life threatening. These severe
complications involve the blood, immune, gastro-intestinal systems, and other vital
organs.

The purpose of this study is to determine if experimental therapy AB-205 (study drug) can
prevent or reduce the occurrence and duration of the severe chemotherapy related
complications when compared to placebo in patients with lymphoma undergoing treatment
with high-dose chemotherapy and blood stem cell transplantation. All patients, whether
treated with AB-205 or placebo, will receive standard preventive and supportive care
therapies.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.